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Our recent Opinion article discussed the oncogenic effects of engaging apoptosis and their impact on 
cancer (Nat. Rev. Cancer 16, 539–548; 2016)1. We would like to thank Roger Chammas, Luciana 
Nogueira de Sousa Andrade and Sonia Jancar for their correspondence on our article (Nat. Rev. 
Cancer (2017) doi:10.1038/nrc.2017.15)2. Caspase protease activity is essential for apoptotic cell 
death. Among hundreds of diverse substrates, caspases cleave Ca2+-independent phospholipase A2 
(iPLA2) leading to its activation3,4; active iPLA2 cleaves phosphatidylcholine to give arachidonic acid 
and lysophosphatidylcholine (LPC). Through cyclooxygenase enzymatic activity, arachidonic acid can 
be converted into prostaglandin E2 (PGE2) — a prostanoid that has tumour-promoting properties. 
Consequently, this provides one means whereby caspase-dependent apoptosis could promote 
cancer5.  
Chammas and colleagues2 highlight oncogenic functions for platelet-activating factor receptor 
(PAFR) signalling; this is mediated following receptor binding to plateletactivating factor (PAF) and 
related PAFR ligands. Various cell-killing anticancer therapies, notably radiation, are strong inducers 
of PAF and PAFR ligands. As the authors discuss, during apoptosis PAF might be produced from LPC 
(generated by caspaseactivated iPLA2) through the action of lysophosphatidylcholine 
acyltransferases (LPCATs). Although we find this possibility interesting, it is unknown whether 
apoptotic cells generate PAF in a caspase-dependent manner. Indeed, radiation and chemotherapies 
induce PAF and PAFR ligands in a nonenzymatic manner (dependent on phospholipid oxidation)6,7, 
arguing against a major role for caspase-dependent generation of PAF. Given this, the rationale for 
directly targeting PAFR signalling in cancer therapy seems more compelling than that for inhibiting 
putative, caspase-dependent PAF generation. 
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